Last $1.52 USD
Change Today +0.02 / 1.33%
Volume 653.7K
As of 3:53 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

stellar biotechnologies inc (SBOTF) Snapshot

Open
$1.49
Previous Close
$1.50
Day High
$1.55
Day Low
$1.49
52 Week High
09/18/13 - $2.30
52 Week Low
07/21/14 - $0.60
Market Cap
121.1M
Average Volume 10 Days
957.9K
EPS TTM
--
Shares Outstanding
78.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STELLAR BIOTECHNOLOGIES INC (SBOTF)

Related News

No related news articles were found.

stellar biotechnologies inc (SBOTF) Related Businessweek News

No Related Businessweek News Found

stellar biotechnologies inc (SBOTF) Details

Stellar Biotechnologies, Inc., a biotechnology company, is engaged in the research, development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH), and related products and technologies to the therapeutic and diagnostic markets in the United States, Europe, and Asia. The company’s KLH is a high molecular weight (HMW) and immune-stimulating protein, which is used in cancers, infectious diseases, and immune disorders, as well as therapeutic vaccines for rheumatoid arthritis and Crohn's disease, systemic lupus erythematosus, lymphoma, metastatic breast cancer, prostate cancer, and other cancers and disorders. Its products include KLH pharmaceutical intermediates; HMW and subunit KLH protein in various grades, formulations, and configurations; and preclinical in vitro diagnostic kits. Stellar Biotechnologies, Inc. is headquartered in Port Hueneme, California.

stellar biotechnologies inc (SBOTF) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $33.3K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $137.5K
Chief Operations Officer
Total Annual Compensation: $155.8K
Chief Technology Officer
Total Annual Compensation: $155.8K
Compensation as of Fiscal Year 2013.

stellar biotechnologies inc (SBOTF) Key Developments

Stellar Biotechnologies, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended May 31, 2014

Stellar Biotechnologies, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended May 31, 2014. For the quarter, the company reported total revenues of $102,581 compared to $73,214 for the same period a year ago. Net income and comprehensive income for the period was $1,813,290 or $0.02 per basic and diluted share compared to loss of $1,171,537 or $0.02 per basic and diluted share for the same period a year ago. Interest income was $16,583 against $1,075 a year ago. Stellar completed the NSF Phase IIB grant during the first quarter of 2014 and generated additional contract and commercial sales revenue during the second and third quarter. For the nine months, the company reported total revenues of $252,848 compared to $250,422 for the same period a year ago. Net loss and comprehensive loss for the period was $3,804,549 or $0.05 per basic and diluted share compared to $5,581,319 or $0.11 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $3,450,095 compared to $2,237,062 for the same period a year ago. Interest income was $43,223 against $3,708 a year ago. The decrease of $2.98 million in net loss for the third quarter of 2014, and cumulative decrease of $1.78 million net loss for the nine months ended May 31, 2014 were substantially affected by fluctuations in noncash change in fair value of warrant liability.

Stellar Biotechnologies, Inc. Announces Auditor Changes

Stellar Biotechnologies, Inc. announced that the resignation of D&H Group LLP, Chartered Accountants, on June 3, 2014, as auditor of the company be accepted, and Moss Adams LLP, Certified Public Accountants, be appointed as auditor of the company to be effective June 3, 2014, to hold office until the next annual meeting at a remuneration to be fixed by the directors.

Stellar Biotechnologies, Inc. Appoints Two Members to Scientific Advisory Board

Stellar Biotechnologies, Inc. announced the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson, D.Sc. to the company's Scientific Advisory Board (SAB). They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D. and Andrew Saxon, M.D. on the SAB. Stellar's SAB is composed of eminent scientists and physicians representing a range of disciplines including immunology, molecular biology and biochemistry. The SAB will be an ongoing resource to provide Stellar's management with counsel and guidance pertaining to the research, development, and clinical application of Stellar's KLH technology. Dr. Gregory Baxter, a member of Stellar's Board of Directors since August 2012, is a Senior Scientist in the Department of Clinical Drug Development for CCS Associates, Inc. Dr. Olson currently serves as Vice President of CMC and Technical Operations for NGM Biopharmaceuticals and Vice President of Protein Sciences for Anthera Pharmacetuicals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBOTF:US $1.52 USD +0.02

SBOTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBOTF.
View Industry Companies
 

Industry Analysis

SBOTF

Industry Average

Valuation SBOTF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 215.0x
Price/Book 10.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 188.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STELLAR BIOTECHNOLOGIES INC, please visit www.stellarbiotechnologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.